A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-06-17
Target enrollment:
Participant gender:
Summary
The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in
combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL)
and further explore schedule variations of NIR178 to optimize immune activation through
inhibition of A2aR.